JA2-WP5 EUnetHTA Joint Action 2 (2012-15)
2014 - PDF

The purpose of the assessment is to evaluate canagliflozin ‘Invokana’ and its use as a treatment of type 2 diabetes mellitus.

Final version of the assessment was published in February 2014

Below is the documentation provided by the Joint Assessment authoring team: